NeurologyLive Friday 5 — November 5, 2021

Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Consortium of Multiple Sclerosis Center 2021: Updates in MS

In a series of interviews with experts in the clinical care of multiple sclerosis (MS), they offer insight into a varying set of topics, including Robert Fox, MD, who spoke to the state of awareness and education on cannabis for patients with MS. More episodes are set to air in the coming days.

2: Podcast: Episode 50: Genetic Testing for Huntington Disease

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Victor Sung, MD, director, UAB Huntington's Disease Clinic, codirector, UAB School of Medicine Neuroscience Module, and director, Birmingham VAMC Deep Brain Stimulation Program, who detailed data on the cost of genetic testing in HD, and the current utilization of it.

3: NeuroVoices: Le Hua, MD, on Siponimod’s Efficacy Regardless of Age

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health provided context on the EXPAND study, which evaluated treatment efficacy and safety in older and younger patients on siponimod (Mayzent; Novartis).

4: FDA Action Update, October 2021: Submissions and Delays

A number of FDA actions took place in October 2021, including application submissions for a number of hopeful therapies for Alzheimer disease (AD), as well as the delay of an anticipated sleep disorder agent. Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive team.

5: The Potential of MCHR1 Antagonists in Narcolepsy: Thomas Scammell, MD

The professor of neurology at Beth Israel Deaconess Medical Center discussed the treatment potential of melanin-concentrating hormone receptor 1 antagonists for narcolepsy, focusing on Harmony Biosciences' HBS-102 (formerly CSTI-100; ConSynance Therapeutics), and a separate compound, called SNAP 94847, that he and colleagues assessed.

—————————————————

Introducing: Giants of Multiple Sclerosis™

Recognize and celebrate the individuals who have achieved landmark successes within multiple sclerosis! Giants of Multiple Sclerosis™ is a premier neuroscience award that celebrates pioneers, innovators, and future generations of leaders who have been selected by their peers for their remarkable achievements in Multiple Sclerosis.

Nominate Someone Today for a 2022 Giants of Multiple Sclerosis™ Award

• Nominations are open through January 31 ,2022
• The Giants of Multiple Sclerosis™ Steering Committee will vet all nominations and vote to determine the 2022 inductees
• Nominees will be selected on the merits of their lifetime work.
• One honoree in each category who makes a measurable difference in the lives of patients will be awarded.
• The 2022 Giants of Multiple Sclerosis™ inaugural class will be announced in Spring of 2022

Nominate someone here.